Entrectinib 2024 medical insurance price

Entrectinib (Entrectinib) is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults; it is also indicated for the treatment of NTRK gene fusion-positive solid tumors in adults and children over 12 years of age who have metastasized or whose surgical resection may result in severe morbidity and have progressed on previous treatment or where no comparable alternative therapy is available. FoundationOne Liquid CDx is the only U.S. Food and Drug Administration (FDA)-approved test to detect ROS1 rearrangements in non-small cell lung cancer and is used to select patients for treatment with entrectinib.

The original drug entrectinib has been launched in the domestic market in the form of capsules and has also been included in the reimbursement scope of medical insurance. For patients who meet the indications for medication, medical insurance can be used to reimburse the cost of medication. Common drug specifications in the domestic market include: 100 mg with 30 pills and 200 mg with 90 pills. Each box is priced at more than 20,000 yuan. Due to different reimbursement ratios in different regions, the price after reimbursement may be different. For specific medical insurance reimbursement and other related information, please consult the local medical insurance bureau or hospital.

Overseas, the European version of the original drug is more expensive. Each box of 200mg*90 tablets may cost more than 40,000 yuan. Of course, this price will be affected by exchange rate fluctuations. In addition, generic drugs of entrectinib are also sold in overseas markets, and their ingredients are basically the same as those of the original drug. For example, the same type of medicine produced by a Lao pharmaceutical factory costs between RMB 1 and more than RMB 6,000 per box. The specific price will also fluctuate due to the exchange rate.